Topiramate Augmentation to a Selective Serotonin Re-Uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo-Controlled Trial.

Trial Profile

Topiramate Augmentation to a Selective Serotonin Re-Uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo-Controlled Trial.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Topiramate (Primary)
  • Indications Social phobia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
    • 09 Apr 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
    • 12 Dec 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top